INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 52 filers reported holding INOZYME PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $570,289 | -20.0% | 135,783 | +6.2% | 0.00% | 0.0% |
| Q2 2023 | $712,443 | -36.3% | 127,907 | -34.4% | 0.00% | -50.0% |
| Q1 2023 | $1,117,906 | +352.6% | 195,097 | +441.4% | 0.00% | – |
| Q4 2021 | $247,000 | -36.2% | 36,033 | +7.9% | 0.00% | -100.0% |
| Q3 2021 | $387,000 | -43.5% | 33,408 | -16.9% | 0.00% | -33.3% |
| Q2 2021 | $685,000 | -33.2% | 40,202 | -22.4% | 0.00% | -40.0% |
| Q1 2021 | $1,026,000 | +214.7% | 51,813 | +317.2% | 0.01% | +150.0% |
| Q3 2020 | $326,000 | – | 12,418 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |